23andMe Holding Co. (ME)

0,4590 -0,0081 (-1,73%) Börsenschluss: 04:00PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300
https://www.23andme.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 769

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Anne Wojcicki	Co-Founder, CEO, President & Chair of the Board	62,92k	N/A	N/A
Mr. Joseph Selsavage	Interim CFO & Accounting Officer	574,56k	N/A	1963
Mr. Eli Fry	Vice President of Operations	N/A	N/A	N/A
Mr. Guy Chayoun	VP, Interim General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Katie Watson	Vice President of Communications	N/A	N/A	1978
Mr. Jonathan Ward	Chief Marketing Officer	N/A	N/A	N/A
Mr. Reza Afkhami M.B.A.	Chief Corporate Development Officer	N/A	N/A	N/A
Ms. Savita Pillai	Vice President of People	N/A	N/A	N/A
Dr. Jennifer Low	Head of Therapeutics Development	N/A	N/A	1969
Mr. Kent Hillyer	Vice President of Consumer Operations	N/A	N/A	1968

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate Governance

23andMe Holding Co.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 3, Vorstand: 8, Shareholderrechte: 10, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.